Publications by authors named "A Flor"
Article Synopsis
- Cannabidiol (CBD) shows promise in treating cardiovascular issues related to neurodegenerative diseases and has previously shown benefits in reducing blood pressure and oxidative stress in acute studies.
- This study aimed to evaluate the long-term effects of chronic CBD treatment specifically on rats with renovascular hypertension induced by a surgical model.
- Results indicated that chronic CBD significantly lowered blood pressure, improved vascular function, and reduced harmful reactive oxygen species, suggesting its potential as a therapeutic option for cardiovascular problems in hypertension.*
Exposure-response modeling for nausea incidence for cotadutide using a Markov modeling approach.
CPT Pharmacometrics Syst Pharmacol
September 2024
Cotadutide is a dual glucagon-like peptide-1 (GLP-1)/glucagon receptor agonist. Gastrointestinal adverse effects are known to be associated with GLP-1 receptor agonism and can be mitigated through tolerance development via a gradual up-titration. This analysis aimed to characterize the relationship between exposure and nausea incidence and to optimize titration schemes.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates familial partial lipodystrophy (FPLD) in Brazil, focusing on its clinical, metabolic, and genetic characteristics through a multicenter analysis involving 106 patients.
- - Results show a high prevalence of diabetes (57.5%), severe hypertriglyceridemia (34.9%), metabolic-associated fatty liver disease (56.6%), and a notable mortality rate linked to cardiovascular issues (3.8%).
- - The findings highlight the need for better understanding and management of FPLD, particularly due to the serious health complications associated with the disorder in this population.
Objective: The aim of this study was to compare the pressure pain threshold and the thickness of the cervical muscles in patients with tension-type headache versus healthy participants.
Methods: An observational, retrospective, cross-sectional study was conducted at the Universidad Europea de Madrid between May and June 2022. Adults aged 18-65 years with tension-type headache diagnosed for more than 6 months were compared to healthy controls.
Background And Objective: Cotadutide is a balanced glucagon-like peptide-1 and glucagon receptor dual agonist under development for the treatment of non-alcoholic steatohepatitis and type 2 diabetes with chronic kidney disease. We evaluated the pharmacokinetics (PK), safety and immunogenicity of a single dose of cotadutide in individuals with varying degrees of renal impairment.
Methods: In this phase I bridging study, individuals 18-85 years of age, with a body mass index of 17-40 kg/m and varying degrees of renal function {end-stage renal disease (ESRD; creatinine clearance [CrCl] < 20 mL/min); severe renal impairment (CrCl ≥ 20 to < 30 mL/min); lower moderate renal impairment (CrCl ≥ 30 to < 44 mL/min); upper moderate renal impairment (CrCl ≥ 45 to < 60 mL/min); normal renal function (CrCl ≥ 90 mL/min)} were treated with a single dose of subcutaneous cotadutide 100 µg under fasted conditions in the lower abdomen.